Wall Street Zen lowered shares of Aldeyra Therapeutics (NASDAQ:ALDX – Free Report) from a hold rating to a sell rating in a report issued on Saturday.
Separately, Weiss Ratings downgraded shares of Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 20th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Aldeyra Therapeutics has a consensus rating of “Hold” and an average target price of $5.50.
Aldeyra Therapeutics Stock Performance
Aldeyra Therapeutics (NASDAQ:ALDX – Get Free Report) last posted its earnings results on Thursday, August 6th. The biotechnology company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). Analysts predict that Aldeyra Therapeutics will post -0.43 EPS for the current fiscal year.
Insider Buying and Selling at Aldeyra Therapeutics
In other news, CEO Todd C. Brady purchased 250,000 shares of Aldeyra Therapeutics stock in a transaction that occurred on Wednesday, June 3rd. The shares were bought at an average cost of $1.67 per share, with a total value of $417,500.00. Following the completion of the purchase, the chief executive officer directly owned 1,721,298 shares in the company, valued at approximately $2,874,567.66. This trade represents a 16.99% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 11.80% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Aldeyra Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Global Retirement Partners LLC bought a new stake in shares of Aldeyra Therapeutics during the 4th quarter valued at $52,000. CIBC Private Wealth Group LLC bought a new position in shares of Aldeyra Therapeutics in the 3rd quarter worth about $55,000. BNP Paribas Financial Markets lifted its position in Aldeyra Therapeutics by 36.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 10,610 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 2,859 shares during the period. SG Americas Securities LLC purchased a new position in Aldeyra Therapeutics during the 4th quarter valued at about $62,000. Finally, Federation des caisses Desjardins du Quebec boosted its stake in Aldeyra Therapeutics by 25.8% during the fourth quarter. Federation des caisses Desjardins du Quebec now owns 12,187 shares of the biotechnology company’s stock worth $63,000 after acquiring an additional 2,500 shares in the last quarter. Hedge funds and other institutional investors own 59.71% of the company’s stock.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.
The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.
Read More
- Five stocks we like better than Aldeyra Therapeutics
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
